Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Mitogen-activated protein kinase (MAPK) pathway dysregulation is implicated in >30% of all cancers, rationalizing the development of RAF, MEK and ERK inhibitors. While BRAF and MEK inhibitors improve BRAF mutant melanoma patient outcomes, these inhibitors had limited success in other MAPK dysregu...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:PLoS One
मुख्य लेखकों: Merchant, Mark, Moffat, John, Schaefer, Gabriele, Chan, Jocelyn, Wang, Xi, Orr, Christine, Cheng, Jason, Hunsaker, Thomas, Shao, Lily, Wang, Stephanie J., Wagle, Marie-Claire, Lin, Eva, Haverty, Peter M., Shahidi-Latham, Sheerin, Ngu, Hai, Solon, Margaret, Eastham-Anderson, Jeffrey, Koeppen, Hartmut, Huang, Shih-Min A., Schwarz, Jacob, Belvin, Marcia, Kirouac, Daniel, Junttila, Melissa R.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Public Library of Science 2017
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628883/
https://ncbi.nlm.nih.gov/pubmed/28982154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0185862
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन